HomeNewsBusinessCompanies3-Point Analysis | Gland Pharma: What should investors do with stock now?

3-Point Analysis | Gland Pharma: What should investors do with stock now?

Gland Pharma's IPO subscription response was tepid compared to the recent entrants. However, it closed 21 percent higher than the issue price of Rs 1500. Let's find out what should investors do post the listing

November 23, 2020 / 19:13 IST
Story continues below Advertisement

Moneycontrol News
first published: Nov 23, 2020 01:53 pm

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!